Masimo’s Pediatric SpO2 Study With Philips Monitors: What Investors Should Watch

Masimo Corp. (MASI) announced an update on their ongoing clinical study.

Masimo Corp. is sponsoring a new clinical study titled “Philips FAST SpO2 Technology With Masimo Sensors for SpO2 Monitoring in the Neonatal, Infant, and Pediatric Populations.” The goal is to confirm how well Philips’ FAST oxygen-monitoring software works when paired with Masimo’s sensors in babies and children with different skin tones. This matters because more accurate and consistent oxygen readings in young patients can improve care and strengthen the value of Masimo’s technology in hospital settings.

The study tests a medical device setup that combines Masimo’s non-invasive RD SET and LNCS sensors with Philips patient monitors running the FAST SpO2 algorithm. The purpose is simple: see if this combined system delivers reliable blood oxygen readings across real-world pediatric patients, using an already cleared Masimo pulse oximeter as a benchmark.

This is an interventional study with one group only. Every enrolled child receives monitoring with the Masimo sensors connected to Philips monitors, alongside readings from an FDA-cleared Masimo pulse oximeter for comparison. There is no random assignment and no blinding, meaning clinicians know which devices are being used. The main focus is practical performance and usability, not treatment outcomes.

The study was first submitted on October 29, 2025, marking the formal start of the project. The trial status is currently “recruiting,” indicating active enrollment of patients. The latest update was posted on January 6, 2026, which signals that the protocol and progress have been recently reviewed and confirmed. Primary and final completion dates have not yet been reported, so investors should assume data are still at an early stage.

For investors, this update suggests Masimo is working to deepen its integration with a major monitor platform in the neonatal and pediatric space, an area where reliability and equity across skin tones are gaining attention. Positive results could support broader hospital adoption, reinforce Masimo’s competitive position in pulse oximetry, and modestly improve sentiment around its core technology franchise. Competitors in patient monitoring and sensors may face more pressure if the partnership with Philips proves both clinically sound and commercially scalable. The study remains ongoing and updated, with more details available on the ClinicalTrials.gov portal under the listed identifier.

To learn more about MASI’s potential, visit the Masimo Corp. drug pipeline page.